Table 1.
Summary of specifications of selected models.
| Model No. | Study | No. of Patients (Total No. of Samples) | Parameter Values and Covariate Relationships Included | IIV (CV) | Residual Variability | 
|---|---|---|---|---|---|
| M1 | FDA, 2008 | 646 adult patients (NA) |  | IIV-CL/F: 16.4% IIV-V/F: 35.1% | Prop = 31.6% | 
| M2 | Ternant D et al., 2015 | 65 adult CD patients (341) |  | IIV-CL/F: 65% IIV-V/F: 48% | Add = 1.8 mg/L Prop = 16% | 
| M3 | Sharma S et al., 2015 | 189 pediatric CD patients (852) |  | IIV-CL/F: 21.1% | Add = 1.9 mg/L Prop = 7.1% | 
| M4 | Berends SE et al., 2018 | 96 adult CD patients (181) |  | IIV-CL/F: 49.1% | Add = 1.02 mg/L Prop = 9% | 
| M5 | Vande Castelee et al., 2019 | 28 adult CD patients (185) |  | IIV-CL/F: 32.6% IIV-V/F: 35.6% IIV-ka: 103.9% | Prop = −16.6% | 
| M6 | Sánchez-Hernández et al., 2020 | 104 adult IBD patients (303) |  | IIV-CL/F: 23.2% | Prop = 21.7% | 
IIV: inter-individual variability; CV: coefficient of variation; CD: Crohn’s disease; IBD: Inflammatory Bowel Disease; WT: weight; AAA: antibodies against adalimumab; DOSING: adalimumab dosing regimen (0: every other week, 1: every week); UDASC: unexplained decline in adalimumab serum concentrations (0: NO, 1: YES); PEN: administration pen device during maintenance phase (0:40 mg, 1:80 mg); FCP: fecal calprotectin; add:additive error; prop: proportional error; NA: not available. The M numbers represent the selected models.